目的 探讨金骨莲胶囊联合艾瑞昔布片治疗膝骨关节炎的临床疗效。方法 选取2024年3月—2025年3月华北医疗健康集团峰峰总医院收治的86例膝骨关节炎患者，按照随机数字表法将患者分为对照组和治疗组，每组各43例。对照组口服艾瑞昔布片，1片/次，2次/d。治疗组在对照组基础上口服金骨莲胶囊，2粒/次，3次/d。两组均治疗8周。比较两组临床疗效、临床症状改善时间、膝关节功能、临床症状改善情况、血清生化指标。结果 治疗组的总有效率高于对照组（P＜0.05）。治疗组的僵硬症状消失时间、膝关节恢复正常活动时间、肿胀症状消失时间短于对照组（P＜0.05）。两组治疗后滑膜厚度、积液深度降低，主动活动度、被动活动度扩大（P＜0.05）；且治疗组滑膜厚度、积液深度低于对照组，主动活动度、被动活动度大于对照组（P＜0.05）。两组治疗后西安大略和麦克马斯特大学骨关节炎指数（WOMAC）、疼痛数字评分表（NRS）评分降低，美国纽约特种外科医院评分系统（HSS）、Lysholm膝关节评分升高（P＜0.05），且治疗组WOMAC、NRS评分低于对照组，HSS、Lysholm膝关节评分高于对照组（P＜0.05）。两组治疗后血清白细胞介素-6（IL-6）、基质金属蛋白酶-13（MMP-13）、高迁移率族蛋白1（HMGB1）、5-羟色胺（5-HT）、多巴胺（DA）水平均显著降低（P＜0.05），且治疗组血清IL-6、MMP-13、HMGB1、5-HT、DA水平低于对照组（P＜0.05）。结论 金骨莲胶囊联合艾瑞昔布片治疗膝骨关节炎可提高临床疗效，有效改善临床症状，促进关节功能恢复，调节血清生化指标水平。

Objective To observe the clinical of Jingulian Capsules combined with Etoricoxib Tablets in treatment of knee osteoarthritis. Methods A total of 86 patients with knee osteoarthritis admitted to Fengfeng General Hospital, North China Medical and Health Group from March 2024 to March 2025 were selected and divided into control group and treatment group according to the random number table method, with 43 cases in each group. The control group was po administered with Etoricoxib Tablets at 1 tablets per dose, twice daily. The treatment group was po administered with Jingulian Capsules on the basis of the control group's regimen, at 2 capsules per dose, three times daily. Two groups were treated for 8 weeks. The clinical efficacy, symptom improvement time, knee joint function, symptom improvement status, and serum biochemical indicators were compared between two groups. Results The total effective rate of the treatment group was higher than that of the control group (P < 0.05). The disappearance times of stiffness symptoms, knee joint recovery time, and swelling symptoms in the treatment group were shorter than those in the control group (P < 0.05). After treatment, the synovium thickness and depth of fluid accumulation decreased in two groups, while the active and passive mobility increased (P < 0.05). And the synovial thickness and depth of fluid accumulation in the treatment group were lower than those in the control group, while the active and passive activity were higher than those in the control group (P < 0.05). After treatment, the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) scale and Pain Numerical Rating Scale (NRS) decreased, while the New York Hospital for Special Surgery (HSS) and Lysholm knee joint scores increased (P < 0.05). The WOMAC and NRS scores of the treatment group were lower than those of the control group, while the HSS and Lysholm knee joint scores were higher than those of the control group (P < 0.05). After treatment, the serum levels of interleukin-6 (IL-6), matrix metalloproteinase-13 (MMP-13), high mobility group protein 1 (HMGB1), serotonin (5-HT), and dopamine (DA) were significantly reduced in two groups (P < 0.05), and the serum levels of IL-6, MMP-13, HMGB1, 5-HT, and DA in the treatment group were lower than those in the control group (P < 0.05). Conclusion The combination of Jingulian Capsules and Etoricoxib Tablets can improve clinical efficacy in treatment of knee osteoarthritis, effectively alleviate clinical symptoms, promote joint function recovery, and regulate serum biochemical indicators.

R982

河北省中医药类科学研究课题计划项目（2023348）